184 related articles for article (PubMed ID: 38183344)
1. A blood-based multi-pathway biomarker assay for early detection and staging of Alzheimer's disease across ethnic groups.
Jiang Y; Uhm H; Ip FC; Ouyang L; Lo RMN; Cheng EYL; Cao X; Tan CMC; Law BCH; Ortiz-Romero P; Puig-Pijoan A; Fernández-Lebrero A; Contador J; Mok KY; Hardy J; Kwok TCY; Mok VCT; Suárez-Calvet M; Zetterberg H; Fu AKY; Ip NY
Alzheimers Dement; 2024 Mar; 20(3):2000-2015. PubMed ID: 38183344
[TBL] [Abstract][Full Text] [Related]
2. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
[TBL] [Abstract][Full Text] [Related]
3. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
[TBL] [Abstract][Full Text] [Related]
4. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
[TBL] [Abstract][Full Text] [Related]
5. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
[TBL] [Abstract][Full Text] [Related]
6. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
[TBL] [Abstract][Full Text] [Related]
7. Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline.
Stockmann J; Verberk IMW; Timmesfeld N; Denz R; Budde B; Lange-Leifhelm J; Scheltens P; van der Flier WM; Nabers A; Teunissen CE; Gerwert K
Alzheimers Res Ther; 2020 Dec; 12(1):169. PubMed ID: 33357241
[TBL] [Abstract][Full Text] [Related]
8. A data-driven model of biomarker changes in sporadic Alzheimer's disease.
Young AL; Oxtoby NP; Daga P; Cash DM; Fox NC; Ourselin S; Schott JM; Alexander DC;
Brain; 2014 Sep; 137(Pt 9):2564-77. PubMed ID: 25012224
[TBL] [Abstract][Full Text] [Related]
9. Higher plasma β-synuclein indicates early synaptic degeneration in Alzheimer's disease.
Oeckl P; Janelidze S; Halbgebauer S; Stomrud E; Palmqvist S; Otto M; Hansson O
Alzheimers Dement; 2023 Nov; 19(11):5095-5102. PubMed ID: 37186338
[TBL] [Abstract][Full Text] [Related]
10. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
[TBL] [Abstract][Full Text] [Related]
11. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
[TBL] [Abstract][Full Text] [Related]
12. Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer's dementia in mild cognitive impairment patients.
Pichet Binette A; Palmqvist S; Bali D; Farrar G; Buckley CJ; Wolk DA; Zetterberg H; Blennow K; Janelidze S; Hansson O
Alzheimers Res Ther; 2022 Mar; 14(1):46. PubMed ID: 35351181
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic and prognostic performance to detect Alzheimer's disease and clinical progression of a novel assay for plasma p-tau217.
Groot C; Cicognola C; Bali D; Triana-Baltzer G; Dage JL; Pontecorvo MJ; Kolb HC; Ossenkoppele R; Janelidze S; Hansson O
Alzheimers Res Ther; 2022 May; 14(1):67. PubMed ID: 35568889
[TBL] [Abstract][Full Text] [Related]
14. Optimizing detection of Alzheimer's disease in mild cognitive impairment: a 4-year biomarker study of mild behavioral impairment in ADNI and MEMENTO.
Ismail Z; Leon R; Creese B; Ballard C; Robert P; Smith EE
Mol Neurodegener; 2023 Jul; 18(1):50. PubMed ID: 37516848
[TBL] [Abstract][Full Text] [Related]
15. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.
Veitch DP; Weiner MW; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
Alzheimers Dement; 2019 Jan; 15(1):106-152. PubMed ID: 30321505
[TBL] [Abstract][Full Text] [Related]
16. Serum IL-6, sAXL, and YKL-40 as systemic correlates of reduced brain structure and function in Alzheimer's disease: results from the DELCODE study.
Brosseron F; Maass A; Kleineidam L; Ravichandran KA; Kolbe CC; Wolfsgruber S; Santarelli F; Häsler LM; McManus R; Ising C; Röske S; Peters O; Cosma NC; Schneider LS; Wang X; Priller J; Spruth EJ; Altenstein S; Schneider A; Fliessbach K; Wiltfang J; Schott BH; Buerger K; Janowitz D; Dichgans M; Perneczky R; Rauchmann BS; Teipel S; Kilimann I; Görß D; Laske C; Munk MH; Düzel E; Yakupow R; Dobisch L; Metzger CD; Glanz W; Ewers M; Dechent P; Haynes JD; Scheffler K; Roy N; Rostamzadeh A; Spottke A; Ramirez A; Mengel D; Synofzik M; Jucker M; Latz E; Jessen F; Wagner M; Heneka MT;
Alzheimers Res Ther; 2023 Jan; 15(1):13. PubMed ID: 36631909
[TBL] [Abstract][Full Text] [Related]
17. T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease.
Haris M; Yadav SK; Rizwan A; Singh A; Cai K; Kaura D; Wang E; Davatzikos C; Trojanowski JQ; Melhem ER; Marincola FM; Borthakur A
Neuroimage Clin; 2015; 7():598-604. PubMed ID: 25844314
[TBL] [Abstract][Full Text] [Related]
18. Electrochemical impedance-based biosensor for label-free determination of plasma P-tau181 levels for clinically accurate diagnosis of mild cognitive impairment and Alzheimer's disease.
Tieu MV; Choi SH; Le HTN; Cho S
Anal Chim Acta; 2023 Sep; 1273():341535. PubMed ID: 37423666
[TBL] [Abstract][Full Text] [Related]
19. Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study.
Brickman AM; Manly JJ; Honig LS; Sanchez D; Reyes-Dumeyer D; Lantigua RA; Lao PJ; Stern Y; Vonsattel JP; Teich AF; Airey DC; Proctor NK; Dage JL; Mayeux R
Alzheimers Dement; 2021 Aug; 17(8):1353-1364. PubMed ID: 33580742
[TBL] [Abstract][Full Text] [Related]
20. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease.
Maass A; Landau S; Baker SL; Horng A; Lockhart SN; La Joie R; Rabinovici GD; Jagust WJ;
Neuroimage; 2017 Aug; 157():448-463. PubMed ID: 28587897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
